Immunocore Holdings Plc Revenue Growth Rates (IMCR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immunocore Holdings Plc  (NASDAQ: IMCR)
 

IMCR's Revenue Growth by Quarter and Year

Immunocore Holdings Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMCR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 115.93
1st Quarter March 106.68
FY 222.61

IMCRs Annual Revenue
Immunocore Holdings Plc's Revenue in the fiscal year 2025 $ 400.02 millions
Immunocore Holdings Plc's Revenue in the fiscal year 2024 $ 310.20 millions
Immunocore Holdings Plc's Revenue in the fiscal year 2023 $ 249.43 millions
Immunocore Holdings Plc's Revenue in the fiscal year 2022 $ 174.36 millions
Immunocore Holdings Plc's Revenue in the fiscal year 2021 $ 36.48 millions




IMCR Revenue second quarter 2026 Y/Y Growth Comment
Immunocore Holdings Plc reported Revenue increase of 18.34% year on year in the second quarter 2026, to $ 115.93 millions, this is lower than Immunocore Holdings Plc's recent average Revenue rise of 63.35%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Revenue growth. While Immunocore Holdings Plc' s Revenue growth of 18.34% ranks overall at the positon no. 1114 in the second quarter 2026.


IMCR Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 24.31 % 19.8 % 44.72 %
3rd Quarter September - 29.21 % 23.75 % 61.28 %
2nd Quarter June 18.34 % 29.92 % 26.17 % 632.35 %
1st Quarter March 13.63 % 33.16 % 28.98 % -
FY   - 28.95 % 24.36 % -

Financial Statements
Immunocore Holdings Plc's second quarter 2026 Revenue $ 115.93 millions IMCR's Income Statement
Immunocore Holdings Plc's second quarter 2025 Revenue $ 97.96 millions Quarterly IMCR's Income Statement


IMCR Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 0.76 % 4.74 % 8.19 %
3rd Quarter September - 5.85 % 6.43 % 8.52 %
2nd Quarter June 8.67 % 4.35 % 6.95 % 9.33 %
1st Quarter March 2.11 % 11.7 % 0.48 % 12.75 %
FY (Year on Year)   - 28.95 % 24.36 % -


Back to IMCR Growth rate Comparisons >> Back to IMCR Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #32
Healthcare Sector #218
Overall #1114

Revenue Y/Y Growth Statistics
High Average Low
493.88 % 63.35 % 13.63 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #32
Healthcare Sector #218
Overall #1114
Revenue Y/Y Growth Statistics
High Average Low
493.88 % 63.35 % 13.63 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Immunocore Holdings Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
20.57 % 7.05 % 0.48 %
(Sep 30 2022)  


IMCR's II. Quarter Q/Q Revenue Comment
Immunocore Holdings Plc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 8.67%, to $ 115.93 millions, from $106.68 millions in the first quarter.
IMCR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Immunocore Holdings Plc's Revenue growth quarter on quarter, overall rank is 894.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #135
Overall #894
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #135
Overall #894
Revenue Q/Q Growth Statistics
High Average Low
20.57 % 7.05 % 0.48 %
(Sep 30 2022)  


IMCR's II. Quarter Q/Q Revenue Comment
Immunocore Holdings Plc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 8.67%, to $ 115.93 millions, from $106.68 millions in the first quarter.
IMCR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Immunocore Holdings Plc's Revenue growth quarter on quarter, overall rank is 894.


Immunocore Holdings Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 430.78 $ 412.81 $ 400.02 $ 379.59 $ 356.15
Y / Y Revenue Growth (TTM) 20.95 % 23.75 % 28.95 % 28.1 % 26.78 %
Year on Year Revenue Growth Overall Ranking # 720 # 699 # 546 # 548 # 568
Seqeuential Revenue Change (TTM) 4.35 % 3.2 % 5.38 % 6.58 % 6.76 %
Seq. Revenue Growth (TTM) Overall Ranking # 720 # 699 # 546 # 548 # 568


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immunocore Holdings Plc's cumulative twelve months Revenue were $ 431 millions, company would post below average annual Revenue growth of 6.76% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immunocore Holdings Plc's Revenue growth from the 333.581% growth in Mar 31 2026.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 699 to 720.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 134
Overall # 637

Revenue TTM Y/Y Growth Statistics
High Average Low
75.09 %
 32.22 %
20.95 %
(Mar 31 2024)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 292
S&P 500 # 1878
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immunocore Holdings Plc's cumulative twelve months Revenue were $ 431 millions, company would post below average annual Revenue growth of 20.95% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immunocore Holdings Plc's Revenue growth from the 333.581% growth in Mar 31 2026.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 699 to 720.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 23
Healthcare Sector # 134
Overall # 637

Revenue TTM Y/Y Growth Statistics
High Average Low
75.09 %
32.22 %
20.95 %
(Mar 31 2024)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 292
S&P 500 # 1878




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IMCR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions
Sight Sciences Inc 25.83%$ 25.830 millions
Grail Inc 25.72%$ 25.723 millions
Fortress Biotech Inc 25.66%$ 25.658 millions
Apyx Medical Corp25.27%$ 25.273 millions
Radnet Inc 24.99%$ 24.986 millions
Precipio inc 24.18%$ 24.178 millions
Krystal Biotech Inc 24.14%$ 24.135 millions
Viemed Healthcare Inc 23.85%$ 23.853 millions
Ardelyx inc 23.77%$ 23.771 millions
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions


About Immunocore Holdings Plc Revenue Growth Rates (IMCR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Immunocore Holdings Plc (CIK 1671927).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001671927-26-000022
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Immunocore Holdings Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.